文献速递免疫规划卫生政策与健康促进

巴西造血干细胞移植受者对Tdap疫苗的免疫应答

Immunological responses to tetanus, diphtheria, pertussis (Tdap) vaccine in Brazilian hematopoietic stem cell transplant recipients.
PubMed 文献 · Vaccine · 2026-01-15

结果显示白喉、破伤风、百日咳抗体水平均显著升高,总体免疫应答被认为充分,且不受临床、人口学或免疫学变量影响。

要点

  • 移植后6个月起接种三剂Tdap,白喉、破伤风、百日咳抗体均显著升高。
  • 百日咳数据经贝叶斯分析确认抗体水平显著增加,可信区间排除零。
  • CD4+细胞频率在整个接种期间保持低水平,但未影响疫苗应答。

核心结论

  • 造血干细胞移植受者完成Tdap全程接种后,对白喉、破伤风、百日咳的总体免疫应答被认为是充分的。

研究设计与样本

  • 免疫方案为移植后6个月起接种三剂Tdap,每剂间隔至少30天。
  • 接种前通过CD4+、CD8+、CD19+频率及血清免疫球蛋白水平评估免疫能力。

主要发现

  • 白喉几何平均浓度(GMC)从基线0.2509 IU/mL升至接种后0.7544 IU/mL,p=0.001。
  • 破伤风GMC从0.353 IU/mL升至1.153 IU/mL,p=0.001。
  • 百日咳GMC接种前31.9 IU/mL、接种后99.3 IU/mL,频率学派p=0.077。
  • 贝叶斯分析(假设指数分布)显示抗体水平显著增加,后验均值差θ=58.55 IU/mL,95%可信区间23.9-109.0排除零。
  • 整个接种期间CD4+细胞频率保持低水平,CD8+、CD19+及免疫球蛋白滴度在正常范围。

临床怎么用

  • 为造血干细胞移植受者按移植后6个月启动、三剂次、间隔至少30天接种Tdap提供免疫原性依据。
  • 提示移植后CD4+细胞频率偏低不一定妨碍对Tdap的抗体应答。

局限性

  • 百日咳数据呈非正态分布,频率学派检验仅为边缘显著(p=0.077),需借助贝叶斯分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Among hematopoietic stem cell transplant (HSCT) recipients, morbidity and mortality are largely related to infectious diseases, many of which are vaccine-preventable. The present study aimed to assess the immune response of HSCT patients to the tetanus, diphtheria, and acellular pertussis inactivated vaccine (Tdap). PATIENTS AND METHODS: This quasi-experimental study, with individually matched data collection in HSCT patients from January 2018 to December 2020, evaluated sixteen patients for their immune response to each of the Tdap components. The immunization schedule included three doses of Tdap, with a minimum interval of 30 days between each dose, starting at 6 months post-transplantation. Immune competence was measured before vaccination by quantifying CD4+, CD8+, and CD19+ frequencies, as well as serum immunoglobulin levels. RESULTS: After the complete immunization schedule, for diphtheria, we observed a Geometric Mean Concentration (GMC) rise from 0.2509 IU/mL at baseline to 0.7544 IU/mL post-vaccination, p = 0.001. For tetanus, GMC increased from 0.353 to 1.153 IU/mL, p = 0.001. For pertussis, GMC was 31.9 IU/mL before and 99.3 IU/mL after vaccination. Due to the non-normal distribution of pertussis data and a marginal frequentist result (p = 0.077), we used Bayesian analysis assuming an exponential distribution. This model identified a significant increase in antibody levels, with a posterior mean difference (θ) of 58.55 IU/mL and a 95% Credibility Interval (23.9-109.0) that excluded zero, confirming an adequate vaccine response. For the entire Tdap vaccination period, CD4+ cell frequencies remained low, while CD8+, CD19+, and immunoglobulin titers remained within normal range. Immune responses to each of the Tdap vaccine components were not affected (p > 0.05) by any of the clinical, demographic, or immunological variables assessed. CONCLUSIONS: The overall Tdap vaccine post-transplant response was considered adequate for diphtheria, tetanus, and pertussis. These findings highlight the immune response to Tdap in transplanted patients and may inform future vaccination guidelines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Paternina-De La Ossa R, Oliveira MC, Achcar JA, et al. Immunological responses to tetanus, diphtheria, pertussis (Tdap) vaccine in Brazilian hematopoietic stem cell transplant recipients. Vaccine. 2026. PMID: 41544367. doi:10.1016/j.vaccine.2026.128250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。